These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6831826)

  • 1. Haloperidol kinetics after oral and intravenous doses.
    Holley FO; Magliozzi JR; Stanski DR; Lombrozo L; Hollister LE
    Clin Pharmacol Ther; 1983 Apr; 33(4):477-84. PubMed ID: 6831826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of haloperidol in psychotic patients.
    Cheng YF; Paalzow LK; Bondesson U; Ekblom B; Eriksson K; Eriksson SO; Lindberg A; Lindström L
    Psychopharmacology (Berl); 1987; 91(4):410-4. PubMed ID: 3108922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
    Patel IH; Levy RH; Bauer TG
    Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
    Chang WH; Lam YW; Jann MW; Chen H
    Psychopharmacology (Berl); 1992; 106(4):517-22. PubMed ID: 1579624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses.
    Nakashima M; Asano M; Ohguchi S; Hashimoto H; Seki T; Miyazaki M; Takenaka T
    Clin Pharmacol Ther; 1984 Oct; 36(4):436-43. PubMed ID: 6478731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
    Magliozzi JR; Hollister LE
    J Clin Psychiatry; 1985 Jan; 46(1):20-1. PubMed ID: 3965439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Propoxyphene kinetics after single oral and intravenous doses in man.
    Gram LF; Schou J; Way WL; Heltberg J; Bodin NO
    Clin Pharmacol Ther; 1979 Oct; 26(4):473-82. PubMed ID: 487695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isosorbide 5-mononitrate kinetics.
    Major RM; Taylor T; Chasseaud LF; Darragh A; Lambe RF
    Clin Pharmacol Ther; 1984 May; 35(5):653-9. PubMed ID: 6713775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin: pharmacokinetics and bioavailability.
    Gugler R; Manion CV; Azarnoff DL
    Clin Pharmacol Ther; 1976 Feb; 19(2):135-42. PubMed ID: 1261151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of oral ergometrine in male volunteers.
    de Groot AN; Vree TB; Hekster YA; van den Biggelaar-Martea M; van Dongen PW; van Roosmalen J
    Biopharm Drug Dispos; 1994 Jan; 15(1):65-73. PubMed ID: 8161717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranitidine bioavailability and kinetics in normal male subjects.
    Garg DC; Weidler DJ; Eshelman FN
    Clin Pharmacol Ther; 1983 Apr; 33(4):445-52. PubMed ID: 6299642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of indomethacin.
    Alván G; Orme M; Bertilsson L; Ekstrand R; Palmér L
    Clin Pharmacol Ther; 1975 Sep; 18(3):364-73. PubMed ID: 1100305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Captopril kinetics.
    Duchin KL; Singhvi SM; Willard DA; Migdalof BH; McKinstry DN
    Clin Pharmacol Ther; 1982 Apr; 31(4):452-8. PubMed ID: 7037265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotoxine kinetics in healthy men after intravenous and oral administration.
    Woodcock BG; Loh W; Habedank WD; Rietbrock N
    Clin Pharmacol Ther; 1982 Nov; 32(5):622-7. PubMed ID: 7128002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and absolute bioavailability of atenolol.
    Mason WD; Winer N; Kochak G; Cohen I; Bell R
    Clin Pharmacol Ther; 1979 Apr; 25(4):408-15. PubMed ID: 428185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.
    Foster TS; Hamann SR; Richards VR; Bryant PJ; Graves DA; McAllister RG
    J Clin Pharmacol; 1983 Apr; 23(4):161-70. PubMed ID: 6863580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection.
    Abernethy DR; Greenblatt DJ; Shader RI
    Clin Pharmacol Ther; 1984 Mar; 35(3):348-53. PubMed ID: 6697642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.